Listed

Takeda Pharmaceutical Co Ltd: Form 20-F for the period ended Mar 31, 2022

Filed with the SEC on Jun 29, 2022 and accepted by EDGAR at Jun 29, 2022, 06:05 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2021-04-01 to 2022-03-31JPY 3.57tnifrs-full:Revenue
Cost of revenue12 months2021-04-01 to 2022-03-31JPY 1.11tnifrs-full:CostOfSales
Operating income12 months2021-04-01 to 2022-03-31JPY 460.84bnifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2021-04-01 to 2022-03-31JPY 72.41bnifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2021-04-01 to 2022-03-31JPY 230.06bnifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2021-04-01 to 2022-03-31JPY 145.87ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2021-04-01 to 2022-03-31JPY 147.14ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2021-04-01 to 2022-03-31JPY 1.12tnifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2021-04-01 to 2022-03-31JPY 123.25bnifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2022-03-31JPY 849.70bnifrs-full:CashAndCashEquivalents
Current assetsAt period end2022-03-31JPY 2.59tnifrs-full:CurrentAssets
Total assetsAt period end2022-03-31JPY 13.18tnifrs-full:Assets
Current liabilitiesAt period end2022-03-31JPY 2.15tnifrs-full:CurrentLiabilities
Total liabilitiesAt period end2022-03-31JPY 7.49tnifrs-full:Liabilities
Shareholders' equityAt period end2022-03-31JPY 5.68tnifrs-full:EquityAttributableToOwnersOfParent

Source: SEC EDGAR, the filing index for accession 0001395064-22-000107. Last ingested by Listed: Nov 5, 2026, 16:17 ET. Listed shows no prices and gives no investment advice.